Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285825 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
A Phase 2 study of Cytopenia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06285825 is a Phase 2 study of Cytopenia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 376-participant average among 11 other Cytopenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06285825, a Phase 2 study of Cytopenia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Conditions Studied
Interventions
- DRUG Emapalumab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06285825
The ClinicalTrials.gov registry entry for NCT06285825 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 11 other Cytopenia trials with a reported enrollment target (91% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Emapalumab is the first listed.
NCT06285825 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06285825 about?
NCT06285825 is a clinical study titled "A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia". To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
What is the current status of trial NCT06285825?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-07-05. Estimated completion is 2028-08-22.
What conditions does trial NCT06285825 study?
This clinical trial studies the following conditions: Cytopenia.
What interventions are being tested in trial NCT06285825?
The interventions under investigation include: Emapalumab (DRUG).
Who is sponsoring clinical trial NCT06285825?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06285825 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.